A Message From Abveris Founder Garren Hilow on the Promotion of Tracey Mullen to CEO
When a leader has the innate ability to help those around them become better, stronger all while...
Abveris is Boston's premier antibody discovery CRO, offering end-to-end mAb discovery services. Our process starts with a thorough project design process, where we work collaboratively with our partners to design a project with the greatest likelihood of success.
Whether you need functional antibodies or you're targeting complex cell surface targets, our technical teams and project managers help deliver the diverse panels of functionally relevant antibodies that meet your project needs. Our services give our partners access to multiple technology platforms with optimized workflows for immunizations, screening, characterization, sequencing, purification, and recombinant production.
Abveris provides a full range of antibody discovery services for monoclonal antibody production, from antigen production to antibody purification, sequencing, and recombinant production. Access to humanized and proprietary mouse platforms, paired with industry-leading screening and characterization technologies provides our team with the ability to design flexible hybridoma or B cell screening workflows tailored to specific downstream applications.
Our team works closely with our partners to develop both therapeutic and reagent antibodies, leveraging as many of our tools as needed to deliver the antibodies our partners need.
When working on novel targets, it can be hard to find a reliable source recombinant protein, and the availability of the necessary cell lines may be limited. With our protein/peptide synthesis and cell line generation capabilities, we ensure appropriate amounts of high-quality immunization and screening material is available.
B Cell screening on Beacon and optimized hybridoma development processes enables the discovery of large, diverse sets of mAbs.
Our suite of high throughput screening and characterization platforms allows us to not only identify ideal binders, but also to screen for high-affinity and functionally relevant antibodies early in the discovery process. High throughput flow cytometry allows us to analyze on-cell binding as well as functional activity.
Next-generation sequencing runs are accompanied by custom data reports highlighting potential developability concerns. Recombinant antibody production allows our partners the option to produce ample amounts of their favorite antibody in a reliable mammalian cell line.
The immune response is critical to successful antibody discovery. Abveris prides itself on its expertise and breadth of immunization capabilities. Immunization methods include:
The hyperimmune response of the DiversimAb mouse can generate appropriate titers in as little as three weeks, enabling rapid antibody discovery. Proprietary adjuvants and proprietary immunization protocols allow our team to exploit the hyperimmune and autoimmune features of our proprietary mouse strain for an even greater chance of cross-reactive and diverse antibodies sets. Through our work with different humanized platforms, we have optimized our immunization methods to apply to the mouse models commonly used for therapeutic discovery campaigns.
Abveris leverages a number of high throughput platforms for antibody screening and characterization. These platforms include TECAN systems for high throughput ELISA, iQue Flow Cytometry for high throughput on cell screening, Carterra SPR and Octet for antibody kinetics analysis.
At Abveris, we deliver high-quality anti-idiotype antibodies using our DiversimAbTM platform. We apply stringent, high content screening in relevant formats predictive of downstream assay success to identify quality reagents for your specific drug development assays (e.g. PK and ADA).
We know these mAbs are critical tools for clinical assay development, and the speed with which we deliver high-quality reagents ultimately impacts patients’ lives. Our team takes pride in the work we perform and prioritizes the delivery of the highest-quality antibodies in industry-leading timelines to support your clinical trials.
Please view the Webinar our COO, Tracey Mullen, hosted that highlights the anti-idiotype discovery workflows that we use with a 94% success rate across diverse targets.
The Beacon platform by Berkeley Lights is a disruptive, best-in-industry technology for single B-cell screening. It enables high resolution screening of antibody secreting B-cells with a throughput and timeline that was unimaginable just a few years ago. Days after tissue collection, the Beacon provides a rich data set about each antibody screened to identify the rare, active, cross-reactive mAbs that are ideal for clinical development. Those antibodies are then sequenced and expressed rapidly to advance them to downstream assays.
The Beacon platform is a perfect combination with Abveris's distinguished ability to generate immune responses in-vivo against difficult-to-target epitopes.
By screening mAbs in for the proper functional activity and cross-reactivity upfront, the process is much more efficient than the age-old method of developing and expressing hundreds or thousands of mAbs to identify the few with relevant function. This results in better mAbs, delivered faster and with less wasted resources.
The limiting factor for most in vivo discovery platforms is the diversity of the host animal's immune response. Abveris is propelled by proprietary hyperimmune, autoimmune engineered mouse strains, DiversimAb and DivergimAb. Due to engineered autoimmune features, our mouse strains offer a competitive advantage in the generation of antibodies to protein targets with high homology to mouse homologs and other cell surface antigens. Common applications of the platform include generation of antibodies with human/mouse/cyno cross-reactivity, antibodies specific to point mutations and mouse anti-mouse surrogate antibodies. Below are a few benefits of the DiversimAb and DivergimAb mouse models:
DiversimAb mice provide an advantage in nearly any custom antibody discovery application due to the increased epitopic diversity of the mAbs resulting from the mice.
Our auto-immune, hyperimmune model enables the delivery of panels of mAbs against targets, and epitopes on those targets, that do not elicit an immune response in natural mice. We've delivered mAbs against 100% mouse proteins out of DiversimAb mice.
We use custom immunization protocols for multi-spanners, high homology targets, and other poor immunogens. Many options available, connect with our team to learn more.
Our DiversimAb platform readily generates species cross-reactive antibodies, including human, cyno and even mouse cross-reactive antibodies.
Immunization strategies optimized for rapid antibody generation without sacrifices in antibody affinity or quality. Identify epitopicly diverse panels of antibodies in weeks, not months.
Our in-house adjuvant suite is stacked with custom formulations that give us an edge for across targets and in-vivo models.
When the discovery of human antibodies is the goal, Abveris can leverage the leading humanized mice in the industry to deliver fully-human, therapeutic-grade antibodies.
We have many years of experience optimizing antibody discovery in engineered mice including the Trianni, Harbour, and Alloy mice. Abveris is a preferred CRO for each of those platforms.
The Abveris expertise and technology platforms enable the delivery of therapeutic-quality antibodies against increasingly challenging targets from humanized mice.
The Trianni MouseTM is a next-generation transgenic mouse platform that contains a complete human antibody repertoire in a single organism. Human Ig gene segments for the heavy, kappa and lambda chains were precisely targeted in place of the deleted mouse segments at all three loci. Native, non-coding murine regulatory elements drive optimal human antibody repertoire production. This unique design combines optimal biological function with FTO for the Trianni Mouse.
The DNA engineering used in the Trianni Mouse provide researchers the best odds of generating leads with good potency, specificity, manufacturability, solubility and low risk of immunogenicity. The platform provides efficient expression of a full human antibody repertoire and, at the same time, maintains the natural immune response of a wild-type mouse.
Abveris applies decades of antibody discovery expertise to unlock the potential of human transgenic mouse models for therapeutic antibody discovery. Using proprietary immunization techniques and special handling procedures for human transgenic mice, we deliver development-ready human antibody drug candidates.
Harbour Antibodies offers access to the H2L2 Harbour Mouse platform for Abveris customer in a de-risked, low-cost "evaluation program" format. Upon successful generation of your lead therapeutic antibodies, you have the opportunity to validate your clones before deciding whether to obtain a commercial license with Harbour Antibodies.
The H2L2 Harbour Mouse is a human transgenic rodent with introduced human antibody V gene families and inactivated murine antibody expression. H2L2 Harbour Mice boasts a diverse V gene usage, affinity maturation, and class switching in vivo. Antigen-specific monoclonal antibodies can be recovered using either hybridomas or B cell screening technologies.
The H2L2 Harbour Mouse technology is covered by US and several international issued and pending patent rights.
The Alloy mice are the newest and most exciting mouse model on the market for antibody discovery. Their flexible business terms and dependable mouse model provide human antibody discovery for a wide breadth of research groups. Having the correct partner that can utilize this platform to its full potential is very important and our close relationship with Alloy has allowed us to optimize our processes to do so.